Alcon Ag · SIX:ALC
Alcon — American Academy of Ophthalmology 2009
34 slides from Alcon's conference presentation, Oct 27, 2009
Slide 1: Alcon Investor Presentation at the American Academy of Ophthalmology
Exhibit 99.1 Alcon Investor Presentation at the American Academy of Ophthalmology October 24, 2009
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation, made on October 24, 2009, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and
Slide 3: Agenda
Agenda Opening Remarks – Kevin Buehler Discussion of Growth Drivers – Bill Barton – Premium IOLs – Surgical Equipment and Disposables – Glaucoma Product Portfolio Question and Answer Session – Kevin Buehler, Bill Barton, Rick Croarkin, Sabri Markabi PhD
Slide 4: Opening Remarks
Opening Remarks Kevin Buehler President and Chief Executive Officer
Slide 5: Opening Remarks
Opening Remarks American Academy of Ophthalmology enables customer focus – Enables best practices and education for doctors – Allows Alcon to maintain close customer relationships – Provides open dialogue to better understand the needs of the future Value of eye care focus and balanced industry lead
Slide 6: Research and Development Strategy
Research and Development Strategy Blend internal research with external licensing, partnerships and acquisitions Create novel, science-based solutions to address unmet medical needs in ophthalmology Target critical areas – Glaucoma – Retinal disease – Dry eye – Cataract Use worldwide capabilities to
Slide 7: Access to New Compounds and Technologies
Access to New Compounds and Technologies AstraZeneca – Exclusive ophthalmic discovery and potential development rights to AstraZeneca’s compound library – Access to multiple classes of small molecules targeting glaucoma, retinal disease, ocular allergy and dry eye – Mutually validated targets and co
Slide 8: Discussion of Growth Drivers
Discussion of Growth Drivers Bill Barton Vice President, International Markets
Slide 9: Product Growth Drivers
Product Growth Drivers Advanced Technology IOLs Surgical Equipment and Disposables Glaucoma Product Portfolio
Slide 10: Product Growth Drivers: Advanced Technology IOLs
Product Growth Drivers Advanced Technology IOLs Surgical Equipment and Disposables Glaucoma Product Portfolio
Slide 11: Advanced Technology IOLs as Source of Growth
Advanced Technology IOLs as Source of Growth AcrySof® IQ Toric Leading toric IOL with approximately 98% U.S. market share IQ technology enhances image quality consistent with NT-IOL class Entry point to advanced technology IOLs for cataract-only doctors AcrySof® IQ Toric AcrySof® IQ ReSTOR® Number o
Slide 12: Substantial Improvement in Intermediate Vision
Substantial Improvement in Intermediate Vision Bilateral Defocus Curve Refraction (D) 1 0.5 0 0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4 -0.1 20/20 0 20/25 logMAR 0.1 20/32 70 cm 0.2 (28 in) 20/40 60 cm 50 cm (20 in) (16 in) 0.3 20/50 0.4 20/63 0.5 ReSTOR® Aspheric +3.0 ReSTOR® Aspheric +4.0 Data on File. Alcon
Slide 13: Improved Vision at All Distances
Improved Vision at All Distances Visual Acuity Comparison of the ReSTOR® Lenses ReSTOR® Aspheric ReSTOR® Aspheric +3.0 +4.0 20/20 or Better 31.2% 8.4% 20/25 or Better 61.6% 21.4% 20/32 or Better 86.2% 49.6% 20/40 or Better 94.9% 71.8% Worse than 20/40 5.1% 28.2% Note: Comparison of AcrySof® ReSTOR®
Slide 14: AcrySof IQ ReSTOR +3.0 Drives PC-IOL Gains
AcrySof® IQ ReSTOR® +3.0 Drives PC-IOL Gains U.S. PC-IOL Market Share U.S. market share has increased 810 basis points since Q4 2008 on strength of IQ ReSTOR® +3.0 60 53.1% 50 47.4% 45.0% (shares by percentage) 40 30 20 10 0 Q2 2008 Q3 2008 Q4 2008 Q1 2009 Q2 2009 Alcon B&L AMO Source: Market Scope
Slide 15: U.S. Cataract Surgery Opportunity
U.S. Cataract Surgery Opportunity Total High Volume Surgeons Percentage of Total Elective IOL Implanting Elective IOLs Procedures by Adoption Classification 28.0% 3,935 648 Surgeons (Ave 70) 31.7% (Ave 13) Elective IOLs per doc 287 (Ave 135) 24.1% 86 (Ave 315) 16.2% Low Adoption (0-50) Medium Adopti
Slide 16: Dr. Warren Hill Discussing AcrySof IQ Toric
Dr. Warren Hill Discussing AcrySof® IQ Toric
Slide 17: Growth Drivers for Advanced Technology IOLs
Growth Drivers for Advanced Technology IOLs Clinical Performance Remove Additional Barriers to Adoption Drive adoption and utilization by surgeons to achieve maximum Integration of AT patient benefit IOLs into Practices Aging Demographics
Slide 18: Alcon at AAO: IOL Topics
Alcon at AAO: IOL Topics AcrySof® IQ ReSTOR® +3.0: My Personal Experience with PC-IOLs Sunday, October 25, 9:00am (Alcon Booth #1501) – Andy Shatz, M.D. AcrySof® IQ ReSTOR® +3.0: Results In My First 50 Patients Sunday, October 25, 12:30pm (Alcon Booth #1501) – Richard Mackool, M.D. AcrySof® IQ Toric
Slide 19: Product Growth Drivers: Surgical Equipment and Disposables
Product Growth Drivers Advanced Technology IOLs Surgical Equipment and Disposables Glaucoma Product Portfolio
Slide 20: U.S. Phaco Machine Share
U.S. Phaco Machine Share U.S. Cataract Equipment Shares Alcon continues to gain share as of Q2 2009 due to INFINITI® INFINITI® with OZil® allows for 16% excellent patient outcomes, >1% safety and efficiency 69% 15% AMO Alcon B&L Other Source: Quarterly Market Scope Cataract Survey
Slide 21: Introduction of OZil iP
Introduction of OZil® iP GN © EET Cemnewozit ©) ‘The Power of Intelligent Phaco. ‘i % ee ss Anticipating every move. Now that's smart. Introducing the intuitively adaptive control of NEW OZiL" IP. Featuring innovative OZil" Intelligent Phaco, the INFINITI" Vision System puts optimized OZil° torsiona
Slide 22: OZil iP Demonstration Video
OZil® iP Demonstration Video
Slide 23: CONSTELLATION Value Proposition
CONSTELLATION® Value Proposition Differentiated from the competition – ULTRAVIT® vitrectomy probe • Operates at 5000 cuts per minute – Integrated IOP control – Improved fluidics – Embedded PUREPOINT® Laser – Benefits of the V-LOCITY® Key features of V-LOCITY® include: – Larger 17” display – Barcode
Slide 24: Constellation Growth Opportunities
Constellation® Growth Opportunities U.S. Vitreoretinal Pak Shares Competitive Goals as of Q2 2009 Conversion of ACCURUS® Installed Base 16% Target High Volume and High Profile Accounts 84% Grow Share through Competitive Conversion Alcon B&L
Slide 25: Surgical Lasers Surgical Diagnostics
Surgical Lasers Surgical Diagnostics
Slide 26: Refractive Competitive Performance
Refractive Competitive Performance Alcon/WaveLight has gained 3 procedure share points U.S. Procedure Share U.S. Procedure Share as of Q4 2007 as of Q2 2009 24% 27% 61% 61% 14% 10% 2% 1% AMO Alcon/WaveLight B&L Nidek Source: Quarterly Market Scope Refractive Surgeon Survey
Slide 27: Alcon at AAO: Equipment Topics
Alcon at AAO: Equipment Topics Initial Experience with New OZil® iP on the INFINITI® Vision System Sunday, October 25, 10:30am (Alcon Booth #1501) – Armando Crema, M.D. and Ivan Ossma, M.D. CONSTELLATION® Vision System: Advancements in Surgical Technology & Efficiency Sunday, October 25, 9:30am (Alc
Slide 28: Product Growth Drivers: Glaucoma Product Portfolio
Product Growth Drivers Advanced Technology IOLs Surgical Equipment and Disposables Glaucoma Product Portfolio
Slide 29: TRAVATAN Family Glaucoma Market Success
TRAVATAN® Family Glaucoma Market Success Alcon Global Prostaglandin Market Share TRAVATAN® Family has gained 6.5 share points 22% following DuoTravTM and TRAVATAN Z® launches 21.1% 20% 18% 16% 14.6% 14% 12% 10% 8% 6% 4% 2% 0% Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 ®
Slide 30: TRAVATAN Z Managed Care Success
TRAVATAN Z® Managed Care Success Top 12 Medicare Part D Plan Performance Formulary Access for MPD 50% Non- Not Preferred preferred Covered 45% 40% -7.4 Lumigan 79.7% 9.9% 10.3% 35% +6.0 Travatan/Z 90.0% 9.3% 0.7% 30% 25% +1.4 Xalatan 41.1% 45.4% 13.5% 20% Top 12 MPD Plans Represent 40% of all Travat
Slide 31: AZARGA Adds to Azopt Growth Opportunity
AZARGA® Adds to Azopt® Growth Opportunity Global TCAI and TCAI Combination Share Global TCAI and TCAI Combination Rx Azopt® Family has gained 11.3 share Azopt® makes up 59.1 percent points since Q2 2005 of the TCAI category 36% 35.2% 34% ® ® AZOPT AZARGA 32% 30% 28% 26% 23.9% 24% Azopt® 22% 20% 18%
Slide 32: Brimonidine 0.15% Launched in October
Brimonidine 0.15% Launched in October U.S. Alpha-Agonists Category Share Alpha-Agonist category has (As of July 2009) annual U.S. sales in excess of $200 million – Brimonidine 0.15% comprises approximately 40% of prescriptions Alcon commenced distribution in the United States in October 40% Revenue
Slide 33: Question and Answer Session
Question and Answer Session Alcon
Slide 34: Alcon Investor Presentation at the American Academy of Ophthalmology
Alcon Investor Presentation at the American Academy of Ophthalmology October 24, 2009